New hope for Tough-to-Treat mesothelioma: targeted therapy trial
NCT ID NCT03007030
Summary
This study is testing whether the drug brentuximab vedotin can help control advanced mesothelioma that has a specific marker called CD30 and cannot be removed by surgery. The drug is designed to target and interfere with cancer cells that have CD30. About 55 patients who have had prior treatments will receive the drug by IV every three weeks to see if it slows or stops their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MESOTHELIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.